Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06058377
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2023-09-27
Brief Title:
Adding an Immunotherapy Drug MEDI4736 Durvalumab to the Usual Chemotherapy Treatment Paclitaxel Cyclophosphamide and Doxorubicin for Stage II-III Breast Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-27
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-27
First Submit QC Date:
September 27 2023
Study First Post Date:
2023-09-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-23
Last Update Post Date:
2024-07-11
Last Update Post Date Type:
ACTUAL